Literature DB >> 23769029

The effect of mTOR-inhibition on NF-κB activity in kidney ischemia-reperfusion injury in mice.

A Kezic1, J U Becker, F Thaiss.   

Abstract

Kidney ischemia-reperfusion injury (IRI) is associated with a robust inflammatory response, which is regulated by nuclear factor-kappaB (NF-κB), mainly its heterodimeric form p65/p50. Considering immunomodulatory properties of mammalian target of rapamycin (mTOR) inhibitors, the effect of everolimus on NF-κB activation in kidney IRI was determined in this study. IRI was induced in C57/BL6 mice by clamping both renal pedicles for 45 minutes. Application of everolimus (0.25 mg/kg bw subcutaneously daily) was started one day before IRI induction. Both everolimus-treated and nontreated mice were sacrificed at several times starting at 30 minutes and finishing on day 7 after IRI induction. The NF-κB activity, proinflammatory cytokines IL-1β, TNF-α, and anti-inflammatory cytokine IL-10 production were determined in kidneys. Compared with nontreated animals, everolimus-treated animals showed significantly increased TNF-α (2741.6 ± 201.72 pg/mg; 1925 ± 185.81 pg/mg, P < .05) and IL-1β (11.47 ± 1.2 pg/mg; 4.3 ± 0.13 pg/mg, P < .01) production on day 2 after IRI induction accompanied by significantly greater NF-κB/DNA binding activity and p65 nuclear expression (P < .01). Two hours after IRI induction, everolimus-treated animals showed significantly increased IL-1β mRNA expression (P < .05) followed by increased IL-1β protein concentrations when compared with nontreated animals measured 6 hours after IRI induction (11.71 ± 1.5 pg/mg; 7.5 ± 1.11 pg/mg, P < .01). Both experimental groups showed increased NF-κB/DNA binding activity at 7 days after IRI induction. Significantly increased nuclear p65 expression was measured in nontreated animals (P < .01), whereas everolimus-treated hosts showed significantly increased nuclear RelB expression (P < .01). These data suggested that everolimus potentiated innate immunity in the early phase of IRI, stimulating the production of NF-κB-driven proinflammatory cytokines such as TNF-α and IL-1β. The NF-κB activity was potentiated under m-TOR inhibition during kidney IRI, implicating a possible beneficial role of alternative NF-κB activation during the repair phase.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23769029     DOI: 10.1016/j.transproceed.2013.02.110

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  11 in total

1.  PGRN induces impaired insulin sensitivity and defective autophagy in hepatic insulin resistance.

Authors:  Jiali Liu; Huixia Li; Bo Zhou; Lin Xu; Xiaomin Kang; Wei Yang; Shufang Wu; Hongzhi Sun
Journal:  Mol Endocrinol       Date:  2015-02-09

2.  Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition.

Authors:  Sumra Nazir; Ihsan Gadi; Moh'd Mohanad Al-Dabet; Ahmed Elwakiel; Shrey Kohli; Sanchita Ghosh; Jayakumar Manoharan; Satish Ranjan; Fabian Bock; Ruediger C Braun-Dullaeus; Charles T Esmon; Tobias B Huber; Eric Camerer; Chris Dockendorff; John H Griffin; Berend Isermann; Khurrum Shahzad
Journal:  Blood       Date:  2017-09-07       Impact factor: 22.113

3.  Aloperine Protects Mice against Ischemia-Reperfusion (IR)-Induced Renal Injury by Regulating PI3K/AKT/mTOR Signaling and AP-1 Activity.

Authors:  Shuang Hu; Yuxing Zhang; Meng Zhang; Yanchao Guo; Ping Yang; Shu Zhang; Sakine Simsekyilmaz; Jun-Fa Xu; Jinxiu Li; Xudong Xiang; Qilin Yu; Cong-Yi Wang
Journal:  Mol Med       Date:  2015-11-03       Impact factor: 6.354

4.  Rapamycin protects kidney against ischemia reperfusion injury through recruitment of NKT cells.

Authors:  Chao Zhang; Long Zheng; Long Li; Lingyan Wang; Liping Li; Shang Huang; Chenli Gu; Lexi Zhang; Cheng Yang; Tongyu Zhu; Ruiming Rong
Journal:  J Transl Med       Date:  2014-08-19       Impact factor: 5.531

5.  Longitudinal follow-up of autophagy and inflammation in brain of APPswePS1dE9 transgenic mice.

Authors:  Arnaud François; Agnès Rioux Bilan; Nathalie Quellard; Béatrice Fernandez; Thierry Janet; Damien Chassaing; Marc Paccalin; Faraj Terro; Guylène Page
Journal:  J Neuroinflammation       Date:  2014-08-27       Impact factor: 8.322

6.  Rapamycin Inhibits Oxidized Low Density Lipoprotein Uptake in Human Umbilical Vein Endothelial Cells via mTOR/NF-κB/LOX-1 Pathway.

Authors:  Yan-De Zhou; Xue-Qin Cao; Zhi-Hua Liu; Yong-Jun Cao; Chun-Feng Liu; Yan-Lin Zhang; Ying Xie
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

Review 7.  Innate Immune Response in Kidney Ischemia/Reperfusion Injury: Potential Target for Therapy.

Authors:  Aleksandra Kezić; Natasa Stajic; Friedrich Thaiss
Journal:  J Immunol Res       Date:  2017-06-06       Impact factor: 4.818

Review 8.  Mitochondria-Targeted Antioxidants: Future Perspectives in Kidney Ischemia Reperfusion Injury.

Authors:  Aleksandra Kezic; Ivan Spasojevic; Visnja Lezaic; Milica Bajcetic
Journal:  Oxid Med Cell Longev       Date:  2016-05-24       Impact factor: 6.543

Review 9.  mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?

Authors:  Aleksandra Kezic; Ljiljana Popovic; Katarina Lalic
Journal:  Oxid Med Cell Longev       Date:  2018-06-24       Impact factor: 6.543

10.  Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane.

Authors:  Annelieke E C A B Willemsen; Jolien Tol; Nielka P van Erp; Marianne A Jonker; Maaike de Boer; Bob Meek; Paul C de Jong; Coline van Moorsel; Winald R Gerritsen; Jan C Grutters; Carla M L van Herpen
Journal:  Target Oncol       Date:  2019-08       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.